LM® LLLT Photobiomodulation Shown as Safe and Effective Management Tool for Chronic Central Serous Chorioretinopathy

Espansione Group, a leading innovator in medtech solutions in ophthalmology and beyond and a pioneer in photobiomodulation technologies, is pleased to announce new and promising preliminary results demonstrating the effectiveness of LM® LLLT (Light Modulation® Low-Level Light Therapy) in managing chronic Central Serous Chorioretiopathy (cCSC).

The case report, discussed for the first time at ARVO 2024 in Seattle, was recently published by Dr. C. Iovino (Italy) et al. on Retinal Cases & Brief Reports Journal (doi: 10.1097/ICB.0000000000001665), representing a testament of the potential of LM® LLLT in Posterior Segment care beyond dAMD.

LM® LLLT (PBM) technology has already been cleared on eye-light® in Europe (MDR) and other geographies for the treatment of Dry Age-Related Macular Degeneration (dAMD) assuring its efficacy, safety and high tolerability.

Case Report

A 55-year-old male patient presenting a giant pigment epithelium detachment (PED) secondary to chronic central serous chorioretinopathy (cCSC) was successfully treated with photobiomodulation (PBM), by the means of an optimized treatment protocol (vis-à-vis the one employed in LightWave clinical trials for dAMD).

SD-OCT showed several small PEDs around the macula in the right eye and a giant macular serous PED with subretinal fluid (SRF) in the LE. FA disclosed multiple hyperfluorescent roundish areas in the posterior pole bilaterally, with a macular pooling in the LE.

SD-OCT of the LE showed a gradual flattening of the macular PED at 3 months, with a complete regression of the latter and of the SRF at 6- and 12-month follow up with no residual signs of chorioretinal atrophy on FAF.

BCVA (ETDRS) improved from 20/80 at baseline to 20/25 at the last follow up, and this functional improvement was further confirmed by MP.

The therapeutic protocol encompassed one session per week for a duration of four weeks, followed by one session bi-weekly for an additional two months.

While additional research efforts are needed to validate this result, this case marks a significant advancement in the application of photobiomodulation technology on eye-light®, showcasing both the effectiveness and potential of this treatment while broadening the scope of LM® LLLT technology.

FIG. 1
The picture delineates the SD-OCT images at baseline (A) which exhibit a pronounced pigment epithelial detachment (PED) with subretinal fluid.

The SD-OCT image at the one-month follow-up (B) reveals a flattening of the PED with the persistence of flat PED accompanied by hyper/hyporeflective material.

The SD-OCT image at the three-month follow-up (C) demonstrates further flattening of the PED.

FIG. 2
The exhibit portrays the baseline fundus autofluorescence (FAF) which exhibits a hyperautofluorescent ring at the periphery of the PED.
The three-month follow-up image reveals isoautofluorescence in the macular region without any legacy of retinal pigment epithelial atrophy.

FIG. 3
The exhibit shows microperimetry (MP) at baseline (A) which shows a reduction in retinal sensitivity in the macular area with a mean value of 7.4 dB. The microperimetry at the three-month follow-up (B) exhibits a significant enhancement in retinal sensitivity in the macular area with a mean value of 26.5 dB.

About Chronic Central Serous Chorioretinopahy

Central serous chorioretinopathy (cCSC / CSCR) is a retinal disorder characterized by localized serous detachment of the macula with or without focal serous pigment epithelial detachment (PED). It is mostly seen in men aged 20–45 years.[1]

Albert V Graefe first described this condition as central recurrent retinitis in 1866. Bennet coined the term “central serous retinopathy,” and Gass described the pathogenesis.[2]

Patients complain of distorted images, the apparent small size of objects, and blurred vision. Most of the cases resolve spontaneously in 3-6 months. For non-resolving cases, treatment includes laser photocoagulation and photodynamic or photobiomodulation therapy.[4], [5]

About Espansione Group

Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.

The company’s certified medical solutions leverage proprietary technologies such as Light Modulation® Low-level Light Therapy (LM® LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.

Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.

For more information, visit www.espansionegroup.it

 Download: Press Release

> Back to Newsroom

Get Started Now

Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

> Get Started